A well-supplied UK & EU sector, led by PRINTING HOUSE LTD, most recent listing 12 months ago.
Clinical services, medical equipment, pharmaceuticals, NHS contracts, and health research.
The German Social Code allows health insurance funds and pharmaceutical companies to enter into framework discount agreements for medications covered by statutory health insurance. In accordance with the relevant legal provisions for public procurement, a regular process of substance-related formal
The Techniker Krankenkasse (TK) aims to establish discount contracts with all suitable pharmaceutical companies for the combination of active ingredients Beclometasone, Formoterol, and Glycopyrronium (ATC: R03AL09) under Section 130a (8) of the Social Code Book V. The contract will be concluded as p
The health insurance funds (whether HEK and/or hkk participate in the respective lot is determined by the designation of the respective lot) aim to enter into discount contracts with all suitable pharmaceutical companies according to § 130a Abs. 8 SGB V for the active ingredients, combinations of ac
This contract opportunity involves the establishment of non-exclusive discount agreements for the pharmaceutical product Epoetin Zeta, as permitted under Section 130a, Paragraph 8 of the German Social Code (SGB V). The GWQ ServicePlus AG, acting on behalf of health insurance companies, is seeking to
The DAK-Gesundheit is seeking suppliers to enter into a non-exclusive discount agreement for the drug Cyanocobalamin (ATC B03BA01) under the provisions of § 130a Abs. 8 SGB V. This agreement will be effective from July 1, 2025, to June 30, 2027, with an option to extend for an additional 12 months.
This contract opportunity involves establishing non-exclusive discount agreements for finished pharmaceuticals with various active ingredients or combinations of active ingredients under an 'Open-House Model' as per § 130a Abs. 8 SGB V. Suppliers can join or sign contracts at any time under the same
The DAK-Gesundheit is seeking suppliers to enter into a non-exclusive discount agreement for the pharmaceutical substances Dolutegravir and Rilpivirine, classified under ATC J05AR21. This agreement will be effective from July 1, 2025, to June 30, 2027. The contract is part of a framework that allows
This contract opportunity involves the establishment of non-exclusive discount contracts for the pharmaceutical product Somatropin, classified under ATC code H01AC01. The contracts will be valid from July 1, 2025, to June 30, 2027, and suppliers can enter into contracts at any time during this perio
This contract opportunity involves the establishment of non-exclusive discount agreements for the pharmaceutical product Denosumab, marketed as Xgeva, in accordance with German social law. The contracts will be valid from July 1, 2025, to June 30, 2027, and suppliers can enter into agreements at any
This contract opportunity involves the establishment of non-exclusive discount agreements for finished pharmaceuticals containing the active ingredient Axitinib (ATC: L01EK01) under an 'open-house model'. All eligible and interested pharmaceutical companies or consortia are invited to enter into or
